Cetrorelix is the company’s lead candidate for the benign prostate hyperplasia indication, and while Aeterna intends to pursue the late-stage clinical development of cetrorelix, Solvay will pursue its current pivotal clinical program with cetrorelix in endometriosis.
Benign prostate hyperplasia is the most common benign tumor in men, and affects more than 50% of men 60 years and over, with approximately 56 million cases in the US, Europe and Japan.
Gilles Gagnon, president of AEterna, was happy with the agreement. “Regaining the BPH rights for cetrorelix is in line with our strategy to move our promising product candidates through our pipeline to become a late-stage biopharmaceutical company.”